News

US FDA approves Verastem's ovarian cancer therapy
The U.S. Food and Drug Administration has approved Verastem's combination therapy for patients with a rare type of ovarian ...
Verastem Ovarian-Cancer Drug Combination Gets FDA Approval -- Update
Accelerated approval was based on the Phase 2 RAMP 201 study that demonstrated a 44% overall response rate in patients with KRAS-mutated recurrent low-grade serous ovarian cancer, the company said.
US FDA approves Verastem's cancer therapy
The U.S. Food and Drug Administration has approved Verastem's combination therapy for patients with a type of ovarian cancer ...